Search Results - "Lijnsvelt, J."

Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module by Egeler, M.D., van Leeuwen, M., Lai-Kwon, J., Eriksson, H., Bartula, I., Elashwah, S., Fox, L., Van Hemelrijck, M., Jefford, M., Lijnsvelt, J., Bagge, A.-S. Lindqvist, Morag, O., Ny, L., Bagge, R. Olofsson, Rogiers, A., Saw, R.P.M., Serpentini, S., Iannopollo, L., Thompson, J., Stiller, H. Tufvesson, Vanlaer, N., van Akkooi, A.C.J., van de Poll-Franse, L.V.

“…We aimed to develop a European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) module tailored for patients with advanced…”
Get full text

Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma by Reijers, I.L.M., Rozeman, E.A., Mallo, H., Uyterlinde, W., Adriaansz, S., Lijnsvelt, J., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.

Get full text

Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra) by Rozeman, E.A., Sikorska, K., Grijpink-Ongering, L., Heeres, B.C., van de Wiel, B.A., Sari, A., Mallo, H., Adriaansz, S., Uyterlinde, W., Lijnsvelt, J., Pronk, L.M., Haanen, J.B.A.G., de Groot, J.W.B., Wilgenhof, S., Vollenbergh, M.A., van Thienen, J.V., Blank, C.U.

Get full text

1175P Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients by Lijnsvelt, J., Lievense, Z., Albers, E., Lopez-Yurda, M., Van De Poll-franse, L.V., Blank, C.U.

Get full text

CN3 Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies by Lijnsvelt, J., Aanes, S.G., Iivanainen, S.M.E., Vitale, M.G., Mentu, S., Arokoski, R., Mohr, P., Addeo, A., Ascierto, P.A., Koivunen, J.P., Haukland, E.C., Blank, C.U.

Get full text

854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI) by Versluis, J.M., Alofs, E., van Thienen, H.V., Wilgenhof, S., Meerveld-Eggink, A., Mallo, H., Uyterlinde, W., Lijnsvelt, J., Haanen, J.B.A.G., Blank, C.U.

Get full text

840P Electronic patient-reported outcomes (ePROs) of adults with BRAF V600–mutant stage III-IV melanoma treated with dabrafenib + trametinib (D + T) collected using the Kaiku Health digital patient (pt) monitoring platform by Lijnsvelt, J., Addeo, A., Vitale, M.G., Mohr, P., Queirolo, P., Ekström, J., Vainio, J., Kataja, V.V., Calado, F., Fagan, A., Lau, M.R., Romero Salas, T., Thole-Glettig, H., Blank, C.U., Ascierto, P.A.

Get full text

1259PSwitch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma by Reijers, I L M, Rozeman, E A, Mallo, H, Uyterlinde, W, Adriaansz, S, Lijnsvelt, J, Wilgenhof, S, van Thienen, J V, Haanen, J B A G, Blank, C U

Get full text

LBA46Phase II study comparing pembrolizumab (PEM) with intermittent/short-term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra) by Rozeman, E A, Sikorska, K, Grijpink-Ongering, L, Heeres, B C, van de Wiel, B A, Sari, A, Mallo, H, Adriaansz, S, Uyterlinde, W, Lijnsvelt, J, Pronk, L M, Haanen, J B A G, de Groot, J W B, Wilgenhof, S, Vollenbergh, M A, van Thienen, J V, Blank, C U

Get full text